Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation

Stock Information for Co-Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Co-Diagnostics Inc.

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics to Present on Co-Dx(TM) PCR Platform and AI Integration at Point-of-Care Testing 2025
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx(TM) PCR Platform to Support Submission to the U.S. FDA
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.